GlassScriptPhysician profile
Emmanuel C Cabe
NPI 1215928791
$6,455.27
in general payments reported to CMS, 2019-2025
33 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $384 · 2021: $293 · 2022: $1,529 · 2023: $1,442 · 2024: $1,359 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,820.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,018.30 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $934.10 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $878.91 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $843.69 | 2021-2025 | |
| Lilly USA, LLC | $793.90 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $252.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.98 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $230.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $203.14 | 2019-2023 | |
| Pfizer INC. | $146.65 | 2019-2025 | |
| Abbott Laboratories | $128.57 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.94 | 2022-2025 | Xifaxan |
| Astellas Pharma US INC | $98.83 | 2020-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $85.19 | 2019-2023 | |
| Axsome Therapeutics, INC. | $46.07 | 2025 | Auvelity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.61 | 2024 | Caplyta |
| Amgen INC. | $39.42 | 2019-2024 | Otezla, Repatha |
| Dexcom, INC. | $37.63 | 2024-2025 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $33.34 | 2023-2024 | Nuzyra |
| Amarin Pharma, INC. | $33.02 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $29.55 | 2019 | |
| Merck Sharp & Dohme LLC | $28.20 | 2020-2025 | Gardasil 9, Capvaxive |
| Antares Pharma, INC. | $27.89 | 2022 | |
| Phathom Pharmaceuticals, INC. | $26.79 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $25.46 | 2023 | Gattex |
| Kowa Pharmaceuticals America, INC. | $19.12 | 2022 | |
| Bioventus LLC | $19.10 | 2024 | Durolane |
| Corium, LLC | $18.69 | 2025 | Azstarys |
| Inspire Medical Systems, INC. | $16.97 | 2023 | Inspire |
| Halozyme INC | $15.77 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $15.12 | 2022 | |
| Allergan, INC. | $14.81 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.80 | 2023 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Cabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.